Abrogation of viral resistance to nucleoside analogues by...

Details Abrogation of viral resistance to nucleoside analogues by... Abrogation of viral resistance to nucleoside analogues by...

A - Human Necessities

61

K

A61K 31/70 (2006.01) A01N 43/04 (2006.01) A61K 31/7084 (2006.01) A61K 39/12 (2006.01) A61P 31/18 (2006.01) C07H 21/02 (2006.01)

Patent

CA 2102221

2102221 9218004 PCTABS00016 The rate of viral resistance developed during the course of treatment with antiviral nucleoside analogues is reduced by administering dsRNAs early in the treatment of the infection or in later stages when viral genetic mutation has occured to restore susceptibility of the virus to otherwise ineffective antiviral agents. Delaying and/or reducing the appearance of nucleoside analogue resistant retroviruses, particularly HIV, is achieved with mismatched dsRNAs notably in the peripheral blood mononuclear cells, especially the CD4 lymphocytes.

Affiliated with

Also associated with

Rating

Abrogation of viral resistance to nucleoside analogues by... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Abrogation of viral resistance to nucleoside analogues by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Abrogation of viral resistance to nucleoside analogues by... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1789603